today announced top-line results from two global Phase III studies of ramucirumab (IMC-1121B), one in advanced gastric cancer and another in metastatic breast cancer. The RAINBOW trial, a global Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback